Last reviewed · How we verify
FK-PC101
FK-PC101 is a small molecule that targets the PD-1/PD-L1 axis.
FK-PC101 is a small molecule that targets the PD-1/PD-L1 axis. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | FK-PC101 |
|---|---|
| Sponsor | Cellvax Therapeutics Inc |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
FK-PC101 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing anti-tumor immune responses.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |